Chart calendar Protalix BioTherapeutics, Inc.

e45acd41e69123fe.j7Xt8RLygubGlZHWua8w1b_Qfsu8wkFligmksakn-i8.64WViyHBtaus2aKBlOhVhODlO4ru8CJS_UvF391Dy3XZ2oWieoLuqYnCoQ~d85675e25f09936fd43e9cc1b60c6e94

Upcoming events on Protalix BioTherapeutics, Inc.

No events available

Past events on Protalix BioTherapeutics, Inc.

11/11/2026

Earnings presentation

12:00 am
11/11/2026

Earnings release - Q3 2026

12/08/2026

Earnings presentation

10:00 pm
12/08/2026

Earnings release - Q2 2026

25/06/2026

Annual General Meeting

10:00 pm
13/05/2026

Earnings presentation

10:00 pm
13/05/2026

Earnings release - Q1 2026

19/03/2026

Earnings release - Annual 2025

18/03/2026

Earnings presentation

11:00 pm
14/11/2025

Earnings release - Q3 2025

14/11/2025

Earnings presentation

12:00 am

Annual results

Fiscal PeriodDecember 2023 2024 2025 2026 2027 2028
Net sales
Million USD
Released
Forecast
Spread
65,5
64,0
2.41%
53,4
53,9
-0.98%
52,7
58,0
-9.03%

87,3


71,0


77,0

EBITDA
Released
Forecast
Spread
0,00
0,00
-
0,00
0,00
-
0,00
0,00
-

0,00


0,00


0,00

EBIT
Million USD
Released
Forecast
Spread
10,5
11,5
-9.12%
3,92
1,44
171.26%
-5,50
-0,83
-563.85%

26,8


6,90


1,13

Earnings before Tax (EBT)
Million USD
Released
Forecast
Spread
8,57
9,56
-10.41%
4,15
1,62
156.18%
-5,61
-0,48
-1061.08%

27,9


9,30


1,71

Net income
Million USD
Released
Forecast
Spread
8,31
8,12
2.31%
2,93
1,22
140.03%
-6,60
-0,75
-775.28%

23,9


8,68


1,52

EPS
USD
Released
Forecast
Spread
0,09
0,11
-14.29%
0,04
0,02
166.67%
-0,08
-0,01
-1500%

0,29


0,11


0,02

Announcement Date14/03/2417/03/2518/03/26-

Quarterly results

Fiscal PeriodSeptember 2025 Q1 2025 Q2 2025 Q3 2025 Q4 2026 Q1 2026 Q2 2026 Q3 2026 Q4 2027 Q1 2027 Q2 2027 Q3 2027 Q4
Net sales
Million USD
Released
Forecast
Spread
10,1
21,6
-53.18%
15,7
13,5
16.11%
17,9
17,9
-0.08%
9,12
14,4
-36.47%
33,8
11,5
194.3%
19,9
12,9
53.86%
21,9
12,3
78.17%

16,1













EBIT
Million USD
Released
Forecast
Spread



1,17
2,20
-46.65%
2,13
4,25
-49.87%
-4,66
0,01
-34603.7%
21,1
-1,42
1587.06%
4,67
-1,32
454.48%
4,05
-4,07
199.48%

0,64













Earnings before Tax (EBT)
Million USD
Released
Forecast
Spread



0,66
2,53
-73.91%
2,24
4,60
-51.28%
-4,78
0,35
-1468.48%
21,1
-1,14
1951.23%
4,86
-1,02
576.24%
4,62
-3,86
219.8%

1,09













Net income
Million USD
Released
Forecast
Spread



0,16
2,38
-93.1%
2,36
4,44
-47%
-5,50
0,21
-2702.36%
18,3
-1,01
1906.41%
3,78
-0,96
491.8%
3,96
-3,67
208.08%

1,03













EPS
USD
Released
Forecast
Spread
-0,05
0,08
-162.5%
0,00
0,03
-
0,03
0,06
-45.45%
-0,07
0,01
-1500%
0,22
-0,01
2300%
0,05
-0,01
600%
0,05
-0,02
350%

0,01


0,01


0,01


0,03


0,06

Announcement Date09/05/2514/08/2513/11/2518/03/2613/05/2612/08/2610/11/26-----
Today

Earnings presentation

12:00 am
14/11/2026

Earnings release - Q2 2027

14/11/2026

Board of Directors Meeting

14/11/2026

Earnings release - Q2 2027

14/11/2026

Board of Directors Meeting

14/11/2026

Earnings release - Q2 2027

16/11/2026

Extraordinary General Meeting

06:00 pm
16/11/2026

Earnings presentation

02:00 pm
16/11/2026

Earnings presentation

03:00 pm
16/11/2026

Earnings release - Q3 2026

Past sector events for Protalix BioTherapeutics, Inc.

Today

Ex-dividend date - 0.235 USD

04:00 pm
13/11/2026

Earnings presentation

12:00 am
Today

Earnings presentation

01:00 pm
Today

Earnings release - Q3 2026

Today

Earnings presentation

04:00 pm
Today

Earnings presentation

09:30 pm
Today

Board of Directors Meeting

Today

Earnings release - Q2 2027

Today

Earnings release - Q2 2027

Today

Board of Directors Meeting

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Protalix BioTherapeutics, Inc.

Quarterly earnings - Rate of surprise

Rate of surprise - EPS - Quarterly - Protalix BioTherapeutics, Inc.

Net sales - Rate of surprise

Rate of surprise - Net sales - Annual - Protalix BioTherapeutics, Inc.

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - Protalix BioTherapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. PLX Stock
  4. Calendar Protalix BioTherapeutics, Inc.